951 Views | 671 Downloads
Correspondence: towonik@emory.edu.
Study design: TKO, ZC, SSR, FRK.
Patient enrolment on study: TKO, RMS, NFS, SP, RNP, SSR, FRK.
Tumor biopsy collection: GZ, TKO, HSK, RMS, RB.
Ex vivo experiments: TKO, GZ, GLS, XD, SS.
Genomic studies: MRR, GLS.
Data analysis and interpretation and manuscript writing: all authors.
The corresponding author had full access to the entire data and vouch for the integrity of the data presented in the manuscript.
We thank Anthea Hammond, Ph.D. for editorial assistance with proof reading the manuscript and helpful suggestion on data presentation.
ASO was generously provided free to all patients enrolled on study by Teva Pharmaceuticals. Teva Pharmaceuticals reviewed the draft manuscript.
The authors declare that they have no competing interests.
This study was supported in part by NIH/NCI 5K23CA164015 Grant award (PI: TK Owonikoko) and the Winship-Kennedy pilot Grant award from the Winship Cancer Institute of Emory University (PI: TK Owonikoko).
Research reported in this publication was also supported in part by the Biostatistics and Bioinformatics Shared resource of Winship Cancer Institute of Emory University and NIH/NCI under award number P30CA138292.
© 2016 Owonikoko et al. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.